CMS excludes obesity drugs from 2026 Medicare coverage, citing cost concerns; Eli Lilly criticizes the decision impacting obesity management treatments.

Comprehensive update on critical U.S. healthcare and insurance issues including Medicaid policy, rural hospital challenges, Medicare Advantage scrutiny, FDA drug approvals, and public health dynamics.

CMS accelerates Medicare price negotiations for drugs with hyaluronidase, impacting biologic drug pricing and pharmaceutical companies like Halozyme Therapeutics and Johnson & Johnson.

President Trump announces an executive order aiming to reduce U.S. prescription drug prices by 30-80% through a 'Most Favored Nation' pricing policy affecting healthcare and insurance markets.

New Medicare Part D rules in 2025 cap oral cancer drug costs at $2,000 annually and introduce a voluntary monthly payment plan to improve affordability for patients.

In 2025, Medicare Part D caps oral cancer drug out-of-pocket costs at $2,000, introducing a monthly payment plan to aid affordability and adherence for beneficiaries.

Pharmaceutical companies increased consumer-directed drug advertising by nearly 30% in early 2025, leveraging tax deductions that affect prescription drug prices, according to AHIP and CSRxP analyses.

Novo Nordisk applies for FDA approval of oral anti-obesity drug following Eli Lilly's clinical success, intensifying competition in the GLP-1 diabetes and weight loss market.

President Trump's executive order prompts potential changes in Medicare drug price negotiation, affecting pharmaceutical pricing, Medicare spending, and FDA drug import regulations. Epic Systems also shifts to a more public presence in healthcare IT.

President Trump's executive order delays Medicare drug price negotiations, favoring pharmaceutical companies and potentially increasing drug costs for the public.